CoSyne Therapeutics

What CoSyne Therapeutics does

CoSyne Therapeutics is a UK-headquartered, privately held biotechnology company founded in 2021 that applies a proprietary "polymathic AI" platform to the discovery of precision pharmaceuticals for high-risk brain cancers, principally glioblastoma and other gliomas. The platform integrates large single-cell datasets and biology foundation models with CRISPRi functional-genomics screening to identify genetic vulnerabilities and matching targeted therapeutics, including subgroup-specific drug repurposing — a published 2025 study demonstrated cytarabine as particularly effective for gliomas with intact TP53 and RB1. CoSyne has described a hub-and-spoke operating model intended to spin out individual drug assets into subsidiaries, supporting a distributed risk-mitigated portfolio approach rather than a single-asset biotech structure.

The company operates with approximately 21 employees (per a 2025 Tracxn profile) across three sites — a computational headquarters in London (Medius House, Soho), an experimental lab embedded at the Milner Therapeutics Institute in Cambridge, and a New York presence — and is led by co-founders Louwai Muhammed (CEO), Liisi Laaniste (CSO) and Michael Johnson (CMO), with a scientific team spanning computational biology, software engineering and experimental biology. As of the inputs, CoSyne is pre-revenue, has raised approximately $8.81M in a single disclosed round from a syndicate of eight early-stage technology and life-sciences investors (including Start Codon, LocalGlobe, Meltwind, Backed and Amino Collective), and the stated commercial model relies on future licensing deals, partnerships or acquisition with pharmaceutical companies once drug candidates reach clinical milestones.

Name

CoSyne Therapeutics

Legal name

CoSyne Therapeutics Limited

Website

https://cosyne.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

CoSyne Therapeutics is a UK biotech, founded in 2021, that uses a proprietary polymathic AI platform with single-cell datasets and CRISPRi screening to discover precision drugs for high-risk brain cancers such as glioblastoma, targeting licensing deals or acquisition with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• AI drug discovery
• Precision medicine
• Brain cancer therapeutics
• Computational biology
• Pharmaceutical R&D

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Drug Development and Licensing: Pre-revenue biotech company focused on developing precision pharmaceuticals for brain cancer. Expected revenue model involves licensing deals or acquisition by pharmaceutical companies after successful clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

CoSyne Therapeutics uses polymathic AI combined with precision medicine to identify and develop targeted drug candidates for brain diseases, particularly high-risk brain cancers such as glioblastoma and gliomas. The company operates a hub-and-spoke model that enables spinning out individual drug assets into subsidiaries, creating a distributed portfolio of best-in-class and first-in-class drug programmes derived from single-cell datasets and biology foundation models.

Product overview

CoSyne Therapeutics is developing a drug discovery platform using polymathic AI for precision medicine targeting brain diseases, particularly high-risk brain cancers. The company operates a Hub-and-spoke model that enables spinning out assets into subsidiaries to create a distributed portfolio. Their pipeline includes a first drug programme aiming to generate a best-in-class asset for neurological diseases and a second programme targeting a universally fatal brain disease.

Differentiator

Problem solved

Functional benefit

Products and services

• Polymathic AI Drug Discovery Platform

Quantifiable outcome

• CRISPRi screening identified cytarabine as particularly effective for gliomas with intact TP53 and RB1

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

One partnership is on record.

• Milner Therapeutics InstitutecoreStrategic or Co-development PartnerCoSyne's experimental lab is based at the Milner Therapeutics Institute, Jeffrey Cheah Biomedical Centre in Cambridge. The institute fosters collaboration among startups, pharma, and academic scientists, focusing on R&D in functional genomics and therapeutics, providing state-of-the-art facilities, networking, and support.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Atomwise: AI-driven small-molecule drug design company using structure-based deep learning. Comparable platform competitor in AI-driven compound identification with pharma partnership history.
• InSilico Medicine: AI-driven biotech operating end-to-end from target identification through clinical development. Directly comparable in AI-first platform approach and pipeline breadth.
• Insitro: AI-driven drug discovery using ML on biological data, with emphasis on data generation and predictive models. Direct peer in AI-for-drug-discovery with larger scale and broader therapeutic scope.
• Exscientia: AI-driven small-molecule drug design company with clinical-stage assets and major pharma partnerships. Closest methodological peer for AI-driven compound design and target prioritization.
• Verge Genomics: AI-driven drug discovery focused on neurological diseases including ALS and Parkinson's using patient genomics data. Most direct peer given overlap in AI platform, neurological disease focus, and use of large genomic datasets.
• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Direct competitor in the AI-for-pharma category, with substantially more capital and partnered programs; overlaps methodologically with CoSyne's polymathic AI approach.
• BenevolentAI: London-based AI drug discovery company using knowledge graphs and ML to identify targets. Direct peer given shared UK base, AI-driven target identification focus, and similar stage and therapeutic-area ambitions.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery spinout from DeepMind using AlphaFold-derived approaches. Operates in the same AI-for-drug-discovery category with vastly greater resources and pharma partnerships.
• Schrödinger: Physics-based computational chemistry and AI platform for drug discovery. Comparable in the AI/computation-for-drug-discovery category with established pharma software business and internal pipeline.

Emerging players

• Kazia Therapeutics: Clinical-stage oncology company with brain cancer programs (e.g., paxalisib for GBM). Therapeutic-area peer for CoSyne's brain cancer focus though differing in modality and platform depth.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CoSyneTx
• GitHubgithub.com/cosyne-therapeutics
• LinkedInlinkedin.com/company/cosyne-therapeutics
• Instagraminstagram.com/cosynetherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoSyne Therapeutics